An Exciting New Research Collaboration
“We intend to quicken the pace of cure research by supporting a collaborative community of leading HIV researchers in one cohesive enterprise.” - Kevin Robert Frost, amfAR Chief Executive Officer
Launched on the eve of World AIDS Day 2015, the amfAR Institute for HIV Cure Research is the centerpiece of our $100 million investment strategy aimed at developing the scientific basis of a cure by the end of 2020.
Established with a five-year $20 million grant to the University of California, San Francisco, the Institute brings together many of the finest minds and most experienced researchers working in the field today.
Under the direction of renowned AIDS researcher Dr. Paul Volberding, teams of investigators are working collaboratively to address the scientific challenges that stand in the way of a cure.
Paul Volberding is the Director of the amfAR Institute for HIV Cure Research at the University of California, San Francisco (UCSF).
What’s New at the Institute?
Deploying New Imaging Techniques for HIV
A Biomarker for the “Active” HIV Reservoir?
UCSF Loses a Revered HIV Scientist
Researchers Report Progress at Cure Summit
Lab Chat: An Interview with Dr. Shomyseh Sanjabi
More ‘Shocks’ in Strategies to Kill Latent HIV
Using Mice to Detect ‘Undetectable HIV’
Aging with HIV: Concerns About Accelerated Heart Disease
Investigators at amfAR Institute for HIV Cure Research deliver progress report
A New Take on an Old Vaccine Idea
Progress, Plans, and the Prospects for a Cure
About the amfAR Institute
amfAR Establishes San Francisco-Based Institute for HIV Cure Research
amfAR Institute for HIV Cure Research: The Work Ahead
Principal Investigators and Collaborating Institutions
Our Moonshot by amfAR CEO Kevin Robert Frost
amfAR’s Countdown to a Cure for AIDS Initiative
amfAR Announces $100 Million Investment Strategy Aimed at Curing HIV